Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198724
Abstract: Introduction: Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment (tx) landscape of CLL/SLL. However, BTKi are associated with an increased risk of bleeding events that may complicate their use in patients (pts) with thrombotic… read more here.
Keywords: first bleed; real world; cll sll; btki ... See more keywords